Two four-marker haplotypes on 7q36.1 region indicate that the potassium channel gene HERG1 (KCNH2, Kv11.1) is related to schizophrenia: A case control study

Behavioral and Brain Functions

Volumn 6, Issue , 2010, Pages

  Atalar, Fatmahan ^a   Acuner, Tufan T ^a   Cine, Naci ^b   Oncu, Fatih ^c   Yesilbursa, Dogan ^c   Ozbek, Ugur ^a   Turkcan, Solmaz ^c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b KOCAELI UNIVERSITY   (Turkey)

^c BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM CHANNEL; ERG1 POTASSIUM CHANNEL; NEUROLEPTIC AGENT; POTASSIUM CHANNEL HERG;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAM; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOSIS; QT INTERVAL; QT PROLONGATION; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; CHEMISTRY; ELECTROCARDIOGRAPHY; GENE LINKAGE DISEQUILIBRIUM; GENETIC MARKER; GENETIC VARIABILITY; GENETICS; LONG QT SYNDROME; PROTEIN TERTIARY STRUCTURE;

ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; GENE FREQUENCY; GENETIC MARKERS; GENETIC VARIATION; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; LONG QT SYNDROME; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN STRUCTURE, TERTIARY; SCHIZOPHRENIA;

EID: 77952683860     PISSN: 17449081     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-9081-6-27     Document Type: Article

References (66)

1. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "just the facts": what we know in 2008. 2. Epidemiology and etiology. Schizophr Res 2008, 102:1-18. 10.1016/j.schres.2008.04.011, 18514488.
2. Keshavan MS, Tandon R, Boutros NN, Nasrallah HA. Schizophrenia, "just the facts": what we know in 2008. Part 3: neurobiology. Schizophr Res 2008, 106:89-107. 10.1016/j.schres.2008.07.020, 18799287.
3. Murray RM, Lappin J, Di Forti M. Schizophrenia: from developmental deviance to dopamine dysregulation. Eur Neuropsychopharmacol 2008, 18(Suppl 3):S129-S134. 10.1016/j.euroneuro.2008.04.002, 18499406.
4. Agid O, Kapur S, Remington G. Emerging drugs for schizophrenia. Expert Opin Emerg Drugs 2008, 13:479-495. 10.1517/14728214.13.3.479, 18764724.
5. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006, 20:389-409. 10.2165/00023210-200620050-00004, 16696579.
6. Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005, 20:15-27. 10.1016/j.eurpsy.2004.11.003, 15642439.
7. Jarskog LF, Miyamoto S, Lieberman JA. Schizophrenia: new pathological insights and therapies. Annu Rev Med 2007, 58:49-61. 10.1146/annurev.med.58.060904.084114, 16903799.
8. Meisenzahl EM, Schmitt GJ, Scheuerecker J, Moller HJ. The role of dopamine for the pathophysiology of schizophrenia. Int Rev Psychiatry 2007, 19:337-345. 10.1080/09540260701502468, 17671867.
9. Dayalu P, Chou KL. Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother 2008, 9:1451-1462. 10.1517/14656566.9.9.1451, 18518777.
10. Pani L, Pira L, Marchese G. Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. Eur Psychiatry 2007, 22:267-275. 10.1016/j.eurpsy.2007.02.005, 17419008.
11. Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F. QT prolongation through hERG K+ channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev 2005, 25:133-166. 10.1002/med.20019, 15389727.
12. Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. J Clin Invest 2005, 115:2025-2032. 10.1172/JCI25539, 1180553, 16075043.
13. Stollberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 2005, 20:243-251. 10.1097/01.yic.0000166405.49473.70, 16096514.
14. Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA 1994, 91:3438-3442. 10.1073/pnas.91.8.3438, 43592, 8159766.
15. Gutman GA, Chandy KG, Grissmer S, Lazdunski M, McKinnon D, Pardo LA, Robertson G, Rudy B, Sanguinetti M, Stuhmer W, Wang X. International Union of Pharmacology LIII: nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 2005, 57:473-508. 10.1124/pr.57.4.10, 16382104.
16. Schwarz JR, Bauer CK. Functions of erg K+ channels in excitable cells. J Cell Mol Med 2004, 8:22-30. 10.1111/j.1582-4934.2004.tb00256.x, 15090257.
17. Vandenberg JI, Torres AM, Campbell TJ, Kuchel PW. The HERG K+ channel: progress in understanding the molecular basis of its unusual gating kinetics. Eur Biophys J 2004, 33:89-97. 10.1007/s00249-004-0419-y, 13680209.
18. Wehrens XHT. Structural determinants of potassium channel blockade and drug-induced arrhythmias. Handb Exp Pharmacol 2005, 171:123-157.
19. Jenkinson DH. Potassium channels: multiplicity and challenges. Br J Pharmacol 2006, 147(Suppl 1):S63-S71. 10.1038/sj.bjp.0706447, 1760724, 16402122.
20. Tamargo J, Caballero R, Gomez R, Valenzuela C, Delpon E. Pharmacology of cardiac potassium channels. Cardiovasc Res 2004, 62:9-33. 10.1016/j.cardiores.2003.12.026, 15023549.
21. Wimmers S, Wulfsen I, Bauer CK, Schwarz JR. Erg1, erg2 and erg3 K channel subunits are able to form heteromultimers. Pflugers Arch 2001, 441:450-455. 10.1007/s004240000467, 11212207.
22. Papa M, Boscia F, Canitano A, Castaldo P, Sellitti S, Annunziato L, Taglialatela M. Expression pattern of the ether-a-gogo-related (ERG) K+ channel-encoding genes ERG1, ERG2, and ERG3 in the adult rat central nervous system. J Comp Neurol 2003, 466:119-135. 10.1002/cne.10886, 14515244.
23. Polvani S, Masi A, Pillozzi S, Gragnani L, Crociani O, Olivotto O, Becchetti A, Wanke E, Arcangeli A. Developmentally regulated expression of the mouse homologues of the potassium channel encoding genes m-erg1, m-erg2 and m-erg3. Gene Expr Patterns 2003, 3:767-776. 10.1016/S1567-133X(03)00124-8, 14643686.
24. Shi W, Wymore RS, Wang HS, Pan Z, Cohen IS, McKinnon D, Dixon JE. Identification of two nervous system-specific members of the erg potassium channel gene family. J Neurosci 1997, 17:9423-9432.
25. Wymore RS, Gintant GA, Wymore RT, Dixon JE, McKinnon D, Cohen IS. Tissue and species distribution of mRNA for the IKR-like K+ channel, erg. Circ Res 1997, 80:261-268.
26. Thomas D, Karle CA, Kiehn J. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr Pharm Des 2006, 12:2271-2283. 10.2174/138161206777585102, 16787254.
27. Witchel HJ. The hERG potassium channel as a therapeutic target. Expert Opin Ther Targets 2007, 11:321-336. 10.1517/14728222.11.3.321, 17298291.
28. Hancox JC, McPate MJ, El Harchi A, Zhang YH. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther 2008, 119:118-132. 10.1016/j.pharmthera.2008.05.009, 18616963.
29. Morita H, Wu J, Zipes DP. The QT syndromes: long and short. Lancet 2008, 372:750-763. 10.1016/S0140-6736(08)61307-0, 18761222.
30. Perrin MJ, Subbiah RN, Vandenberg JI, Hill AP. Human ether-a-go-go-related gene (hERG) K+ channels: function and dysfunction. Prog Biophys Mol Biol 2008, 98:137-148. 10.1016/j.pbiomolbio.2008.10.006, 19027781.
31. Saenen JB, Vrints JC. Molecular aspects of the congenital and acquired long QT syndrome: clinical implications. J Mol Cell Cardiol 2008, 44:633-646. 10.1016/j.yjmcc.2008.01.006, 18336833.
32. Stone JM, Pilowsky LS. Novel targets for drugs in schizophrenia. CNS Neurol Disord Drug Targets 2007, 6:265-272. 10.2174/187152707781387323, 17691983.
33. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007, 13:13-24. 10.1097/00131746-200701000-00003, 17242588.
34. Kim DH, Maneen MJ, Stahl SM. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics 2009, 6:78-85. 10.1016/j.nurt.2008.10.020, 19110200.
35. Huffaker SJ, Chen J, Nicodemus KK, Sambataro F, Yang F, Mattay V, Lipska BK, Hyde TM, Song J, Rujescu D, Giegling I, Mayilyan K, Proust MJ, Soghoyan A, Caforio G, Callicott JH, Bertolino A, Meyer-Lindenberg A, Chang J, Ji Y, Egan MF, Goldberg TE, Kleinman JE, Lu B, Weinberger DR. A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nat Med 2009, 15:509-518. 10.1038/nm.1962, 2756110, 19412172.
36. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, Washington DC: American Psychiatric Association, 4, American Psychiatric Association.
37. Goldenberg I, Zareba W, Moss AJ. Long QT syndrome. Curr Probl Cardiol 2008, 33:629-694. 10.1016/j.cpcardiol.2008.07.002, 18835466.
38. International Conference on Harmonisation Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs 2005, Rockville: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, International Conference on Harmonisation.
39. International Conference on Harmonisation ICH Topic E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs 2005, London: European Medicines Agency, International Conference on Harmonisation.
40. Pfeufer A, Jalilzadeh S, Perz S, Mueller JC, Hinterseer M, Illig T, Akyol M, Huth C, Schopfer-Wendels A, Kuch B, Steinbeck G, Holle R, Nabauer M, Wichmann HE, Meitinger T, Kaab S. Common variants in myocardial ion channel genes modify the QT interval in the general population: results from the KORA study. Circ Res 2005, 96:693-701. 10.1161/01.RES.0000161077.53751.e6, 15746444.
41. KBiosciences. , http://kbioscience.co.uk
42. International HapMap Project. , http://hapmap.ncbi.nlm.nih.gov
43. Jindal RD, Keshavan MS. Neurobiology of the early course of schizophrenia. Expert Rev Neurother 2008, 8:1093-1100. 10.1586/14737175.8.7.1093, 18590479.
44. Lang UE, Puls I, Muller DJ, Strutz-Seebohm N, Gallinat J. Molecular mechanisms of schizophrenia. Cell Physiol Biochem 2007, 20:687-702. 10.1159/000110430, 17982252.
45. Guasti L, Cilia E, Crociani O, Hofmann G, Polvani S, Becchetti A, Wanke E, Tempia F, Arcangeli A. Expression pattern of the ether-a-go-go-related (ERG) family proteins in the adult mouse central nervous system: evidence for coassembly of different subunits. J Comp Neurol 2005, 491:157-174. 10.1002/cne.20721, 16127690.
46. Saganich MJ, Machado E, Rudy B. Differential expression of genes encoding subthreshold-operating voltage-gated K+ channels in brain. J Neurosci 2001, 21:4609-4624.
47. Hirdes W, Schweizer M, Schuricht KS, Guddat SS, Wulfsen I, Bauer CK, Schwarz JR. Fast erg K+ currents in rat embryonic serotonergic neurones. J Physiol 2005, 564:33-49. 10.1113/jphysiol.2004.082123, 1456054, 15677682.
48. Wimmers S, Bauer CK, Schwarz JR. Biophysical properties of heteromultimeric erg K+ channels. Pflugers Arch 2002, 445:423-430. 10.1007/s00424-002-0936-4, 12466946.
49. Hardman RM, Forsythe ID. Ether-a-go-go-related gene K+ channels contribute to threshold excitability of mouse auditory brainstem neurons. J Physiol 2009, 587:2487-2497. 10.1113/jphysiol.2009.170548, 2714015, 19359372.
50. Chiesa N, Rosati B, Arcangeli A, Olivotto M, Wanke E. A novel role for HERG K+ channels: spike-frequency adaptation. J Physiol 1997, 501:313-318. 10.1111/j.1469-7793.1997.313bn.x, 1159479, 9192303.
51. Einarsen K, Calloe K, Grunnet M, Olesen SP, Schmitt N. Functional properties of human neuronal Kv11 channels. Pflugers Arch 2009, 458:689-700. 10.1007/s00424-009-0651-5, 19319565.
52. Pessia M, Servettini I, Panichi R, Guasti L, Grassi S, Arcangeli A, Wanke E, Pettorossi VE. ERG voltage-gated K+ channels regulate excitability and discharge dynamics of the medial vestibular nucleus neurones. J Physiol 2008, 586:4877-4890. 10.1113/jphysiol.2008.155762, 2614050, 18718985.
53. Sacco T, Bruno A, Wanke E, Tempia F. Functional roles of an ERG current isolated in cerebellar purkinje neurons. J Neurophysiol 2003, 90:1817-1828. 10.1152/jn.00104.2003, 12750425.
54. Nedergaard S. A Ca2+-independent slow afterhyperpolarization in substantia nigra compacta neurons. Neuroscience 2004, 125:841-852. 10.1016/j.neuroscience.2004.02.030, 15120845.
55. Canavier CC, Oprisan SA, Callaway JC, Ji H, Shepard PD. Computational model predicts a role for ERG current in repolarizing plateau potentials in dopamine neurons: implications for modulation of neuronal activity. J Neurophysiol 2007, 98:3006-3022. 10.1152/jn.00422.2007, 17699694.
56. Crociani O, Cherubini A, Piccini E, Polvani S, Costa L, Fontana L, Hofmann G, Rosati B, Wanke E, Olivotto M, Arcangeli A. erg gene(s) expression during development of the nervous and muscular system of quail embryos. Mech Dev 2000, 95:239-243. 10.1016/S0925-4773(00)00335-X, 10906470.
57. Feuk L, Carson AR, Scherer SW. Structural variation in the human genome. Nat Rev Genet 2006, 7:85-97. 10.1038/nrg1767, 16418744.
58. Henrichsen CN, Chaignat E, Reymond A. Copy number variants, diseases and gene expression. Hum Mol Genet 2009, 18(Review Issue 1):R1-R8. 10.1093/hmg/ddp011, 19297395.
59. Reynolds GP. Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 2004, 18:340-345. 10.1177/026988110401800303, 15358977.
60. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005, 10:79-104. 10.1038/sj.mp.4001556, 15289815.
61. Kang J, Chen XL, Rampe D. The antipsychotic drugs sertindole and pimozide block erg3, a human brain K+ channel. Biochem Biophys Res Commun 2001, 286:499-504. 10.1006/bbrc.2001.5434, 11511086.
62. Rampe D, Murawsky MK, Grau J, Lewis EW. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 1998, 286:788-793.
63. Shepard PD, Canavier CC, Levitan ES. Ether-a-go-go-related gene potassium channels: what's all the buzz about?. Schizophr Bull 2007, 33:1263-1269. 10.1093/schbul/sbm106, 2779881, 17905786.
64. Richtand NM, McNamara RK. Serotonin and dopamine interactions in psychosis prevention. Prog Brain Res 2008, 172:141-153. full_text, 18772031.
65. Craddock N, O'Donovan MC, Owen MJ. Psychosis genetics: modeling the relationship between schizophrenia, bipolar disorder, and mixed (or "schizoaffective") psychoses. Schizophr Bull 2009, 35:482-490. 10.1093/schbul/sbp020, 2669589, 19329560.
66. Tan HY, Callicott JH, Weinberger DR. Intermediate phenotypes in schizophrenia genetics redux: is it a no brainer?. Mol Psychiatry 2008, 13:233-238. 10.1038/sj.mp.4002145, 18285755.